Immunotherapy researchers detail improved effectiveness data of tisagenlecleucel CAR T-cell therapy

December 21, 2018

Scientists from the Children’s Hospital of Philadelphia (CHOP) revealed new safety and effectiveness data on tisagenlecleucel, the first FDA approved individualized CAR T-cell gene immunotherapy for aggressive blood cancers at the latest annual meeting of the American Society of Hematology (ASH).

As presented by Stephan Grupp, MD, Ph.D., Director of the Cancer Immunotherapy Program, treatment with ELIANA, the first and only pediatric global CAR-T cell therapy trial of tisagenlecleucel, resulted in an 82% remission rate only 3 months after one infusion. Furthermore, 62% of individuals experienced relapse free survival after 24 months.

Read More

New Treatments and Research

Leave a Comment

Your email address will not be published. Required fields are marked *

Previous reading
Newly developed childhood cancer insights
Next reading
Newly developed biosensors can determine if cancer is likely to spread